Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort

Body mass index predicts discontinuation due to ineffectiveness and female sex predicts discontinuation due to side-effects in patients with psoriasis treated with adalimumab, etanercept or ustekinumab in daily practice: a prospective, comparative, long-t

(2016) J. Zweegers et al.   BRITISH JOURNAL OF DERMATOLOGY

Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR])

(2016) Bruce E. Strober et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Long-Term Efficacy, Safety and Drug Survival of Ustekinumab in a Spanish Cohort of Patients with Moderate to Severe Plaque Psoriasis

(2015) Lluís Puig et al.   DERMATOLOGY

Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

(2015) Richard B. Warren et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis

(2015) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Comparing treatment goals for psoriasis with treatment decisions in daily practice: results from a prospective cohort of patients with psoriasis treated with biologics: BioCAPTURE

(2014) J. Zweegers et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term efficacy and safety of infliximab maintenance therapy in patients with plaque-type psoriasis in real-world practice

(2014) N.H. Shear et al.   BRITISH JOURNAL OF DERMATOLOGY

‘Happy’ drug survival of adalimumab, etanercept and ustekinumab in psoriasis in daily practice care: results from the BioCAPTURE network

(2014) J.M.P.A. van den Reek et al.   BRITISH JOURNAL OF DERMATOLOGY

Drug survival is not significantly different between biologics in patients with psoriasis vulgaris: a single-centre database analysis

(2014) S.P. Menting et al.   BRITISH JOURNAL OF DERMATOLOGY

The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial

(2014) Nawaf Al-Mutairi et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

PASI90 response: the new standard in therapeutic efficacy for psoriasis

(2014) L. Puig   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study

(2013) M. Esposito et al.   BRITISH JOURNAL OF DERMATOLOGY

Diet and physical exercise in psoriasis: a randomized controlled trial

(2013) L. Naldi et al.   BRITISH JOURNAL OF DERMATOLOGY

Determinants of drug survival for etanercept in a long-term daily practice cohort of patients with psoriasis

(2013) J.M.P.A. van den Reek et al.   BRITISH JOURNAL OF DERMATOLOGY

Long-term study of infliximab for psoriasis in daily practice: drug survival depends on combined treatment, obesity and infusion reactions

(2013) J. Spertino et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies

(2013) P.L. Mattei et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry

(2013) J.M. Carrascosa et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The Higher Proportion of Men with Psoriasis Treated with Biologics May Be Explained by More Severe Disease in Men

(2013) David Hägg et al.   PLoS One

Adalimumab therapy for psoriasis in real-world practice: efficacy, safety and results in biologic-naïve vs. non-naïve patients

(2012) P.P.M. van Lümig et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Implementing treatment goals for successful long-term management of psoriasis

(2012) U. Mrowietz   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

Dramatic impact of a Psoriasis Area and Severity Index 90 response on the quality of life in patients with psoriasis: An analysis of Japanese clinical trials of infliximab

(2011) Hideshi TORII et al.   JOURNAL OF DERMATOLOGY

Definition of treatment goals for moderate to severe psoriasis: a European consensus

(2010) U. Mrowietz et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

European S3-Guidelines on the systemic treatment of psoriasis vulgaris

(2009) D Pathirana et al.   JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY

The relationship between quality of life and skin clearance in moderate-to-severe psoriasis: lessons learnt from clinical trials with infliximab

(2008) Kristian Reich et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial

(2007) Alan Menter et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY